Thursday , October 17th , 2019  

Ghana’s Grains and Groundnuts Face Increasing Contamination Amid Increasing Temperatures

Ghanian smallholder farmer Regina Dabiali says they are increasingly losing out on harvests as their grains are becoming affected by aflatoxins. Courtesy: Albert Oppong-Ansah/IPS By Albert Oppong-AnsahBONO EAST REGION, Ghana , Oct 16 2019 – Adwoa Frimpomaah, a smallholder farmer from Dandwa, a farming community in Nkoranza, in Ghana’s Bono East Region, and her two children have been...

Holding Transnational Corporations Accountable for Human Rights Abuses

Shayda Naficy is a Senior Program Director at Corporate Accountability. Her areas of expertise include international human rights, global democracy movements, and water privatization and water management*.   Ebuata Philip Jakpor, a journalist and passionate advocate for environmental justice, is currently Programme Manager with the Environmental Rights Action/Friends of the Earth Nigeria. By...

Sol-Gel to Present on Potential of Sol-Gel Microencapsulation Technology in Rosacea at 39th Annual Fall Clinical Dermatology Conference

NESS ZIONA, Israel, Oct. 16, 2019 (GLOBE NEWSWIRE) — Sol–Gel Technologies, Ltd. (NASDAQ: SLGL) today announced it will present research on the use of its proprietary microencapsulation technology in treating papulopustular rosacea, including Phase 3 results for Epsolay microencapsulated benzoyl peroxide cream, 5% (E–BPO), at the 39th Annual Fall Clinical Dermatology Conference...

Sol-Gel to Present on Potential of Sol-Gel Microencapsulation Technology in Rosacea at 39th Annual Fall Clinical Dermatology Conference

NESS ZIONA, Israel, Oct. 16, 2019 (GLOBE NEWSWIRE) — Sol–Gel Technologies, Ltd. (NASDAQ: SLGL) today announced it will present research on the use of its proprietary microencapsulation technology in treating papulopustular rosacea, including Phase 3 results for Epsolay microencapsulated benzoyl peroxide cream, 5% (E–BPO), at the 39th Annual Fall Clinical Dermatology Conference...

Sol-Gel to Present on Potential of Sol-Gel Microencapsulation Technology in Rosacea at 39th Annual Fall Clinical Dermatology Conference

NESS ZIONA, Israel, Oct. 16, 2019 (GLOBE NEWSWIRE) — Sol–Gel Technologies, Ltd. (NASDAQ: SLGL) today announced it will present research on the use of its proprietary microencapsulation technology in treating papulopustular rosacea, including Phase 3 results for Epsolay microencapsulated benzoyl peroxide cream, 5% (E–BPO), at the 39th Annual Fall Clinical Dermatology Conference...

Sol-Gel to Present on Potential of Sol-Gel Microencapsulation Technology in Rosacea at 39th Annual Fall Clinical Dermatology Conference

NESS ZIONA, Israel, Oct. 16, 2019 (GLOBE NEWSWIRE) — Sol–Gel Technologies, Ltd. (NASDAQ: SLGL) today announced it will present research on the use of its proprietary microencapsulation technology in treating papulopustular rosacea, including Phase 3 results for Epsolay microencapsulated benzoyl peroxide cream, 5% (E–BPO), at the 39th Annual Fall Clinical Dermatology Conference...

Sol-Gel to Present on Potential of Sol-Gel Microencapsulation Technology in Rosacea at 39th Annual Fall Clinical Dermatology Conference

NESS ZIONA, Israel, Oct. 16, 2019 (GLOBE NEWSWIRE) — Sol–Gel Technologies, Ltd. (NASDAQ: SLGL) today announced it will present research on the use of its proprietary microencapsulation technology in treating papulopustular rosacea, including Phase 3 results for Epsolay microencapsulated benzoyl peroxide cream, 5% (E–BPO), at the 39th Annual Fall Clinical Dermatology Conference...

Sol-Gel to Present on Potential of Sol-Gel Microencapsulation Technology in Rosacea at 39th Annual Fall Clinical Dermatology Conference

NESS ZIONA, Israel, Oct. 16, 2019 (GLOBE NEWSWIRE) — Sol–Gel Technologies, Ltd. (NASDAQ: SLGL) today announced it will present research on the use of its proprietary microencapsulation technology in treating papulopustular rosacea, including Phase 3 results for Epsolay microencapsulated benzoyl peroxide cream, 5% (E–BPO), at the 39th Annual Fall Clinical Dermatology Conference...

Sol-Gel to Present on Potential of Sol-Gel Microencapsulation Technology in Rosacea at 39th Annual Fall Clinical Dermatology Conference

NESS ZIONA, Israel, Oct. 16, 2019 (GLOBE NEWSWIRE) — Sol–Gel Technologies, Ltd. (NASDAQ: SLGL) today announced it will present research on the use of its proprietary microencapsulation technology in treating papulopustular rosacea, including Phase 3 results for Epsolay microencapsulated benzoyl peroxide cream, 5% (E–BPO), at the 39th Annual Fall Clinical Dermatology Conference...

Sol-Gel to Present on Potential of Sol-Gel Microencapsulation Technology in Rosacea at 39th Annual Fall Clinical Dermatology Conference

NESS ZIONA, Israel, Oct. 16, 2019 (GLOBE NEWSWIRE) — Sol–Gel Technologies, Ltd. (NASDAQ: SLGL) today announced it will present research on the use of its proprietary microencapsulation technology in treating papulopustular rosacea, including Phase 3 results for Epsolay microencapsulated benzoyl peroxide cream, 5% (E–BPO), at the 39th Annual Fall Clinical Dermatology Conference...